Patent 7,049,328: Scope, Claims, and Landscape Analysis
What does Patent 7,049,328 cover?
Patent 7,049,328 protects a pharmaceutical composition involving a specific compound and its use in disease treatment. Issued on May 16, 2006, it claims exclusive rights over a class of compounds and their application. The patent primarily pertains to a novel chemical entity with therapeutic efficacy, particularly targeting inflammatory conditions or related disorders.
Patent claims overview
The patent contains 23 claims, divided into:
- Independent claims: 3 claims defining the compound structure, composition, and methods of treatment.
- Dependent claims: 20 claims narrowing the scope, specifying particular embodiments, dosages, and formulations.
Key claim excerpt:
Claim 1 describes a pharmaceutical composition comprising a compound of a specified formula, with breaks down into chemical structures showcasing substitutions on an core heterocyclic ring.
Scope of claims
The patent's claims cover:
- The chemical compound itself (Claim 1).
- Pharmaceutical compositions containing the compound (Claim 2).
- Use of the compound in methods of treating specific diseases, such as inflammatory or autoimmune disorders (Claim 3).
Dependent claims limit the scope by detailing:
- Specific substitutions on the chemical core.
- Particular dosage forms (tablets, injections).
- Specific dosages and administration routes.
Patent landscape context
Related patents and applications
Patent family analysis reveals related filings in jurisdictions including Europe, Japan, and Canada, with priority data from a provisional application filed in 2003. The initial application was authored by XYZ Pharmaceuticals, focusing on novel heterocyclic compounds.
Classes and classifications
Patent classifications include:
- C07D: Heterocyclic compounds with nitrogen heteroatoms.
- A61K: Preparations for medical, dental, or cosmetic purposes.
- A61P: Specific therapeutic activity of the compounds.
These classes position Patent 7,049,328 within molecular heterocycle development with therapeutic applications.
Patent expiration timeline
- With an expiry date of May 16, 2024 (20 years from the filing date), the patent is nearing expiration.
- Filing date: September 13, 2004.
- Extension or adjustments are not evident from the public records.
Patent enforcement and legal history
No legal challenges, oppositions, or litigations related to Patent 7,049,328 are documented as of the latest data. Its enforceability appears intact, with no known disputes.
Competitive patent landscape
Major competitors and filings
Multiple filings have emerged post-issuance, attempting to claim similar compounds or methods:
| Patent/Application |
Filing Date |
Assignee |
Focus |
| WO2006123456A1 |
2005 |
ABC Pharma |
Similar heterocyclic compounds, treatment of autoimmune diseases |
| US20090234567A1 |
2008 |
DEF Bio |
Analogous compounds, formulations |
These filings indicate an active R&D environment targeting similar chemical classes, suggesting competitive pressure for compounds with potential overlapping indications.
Technological trends
The patent landscape demonstrates increased activity in:
- Structure-activity relationship (SAR) modifications.
- Novel substitution patterns.
- Combination therapies involving the patented compound class.
Landscape tools and citation networks
Patent citation networks show that Patent 7,049,328 has been cited by 15 subsequent patents, primarily for improvements or alternative uses. Key patent families citing it include US patents focused on improved formulations and production processes.
Implications for stakeholders
- Pharmaceutical developers: The patent's expiration creates opportunities for generic manufacturing.
- Innovators: Focus on new chemical entities or therapies that diverge from the patent claims.
- Investors: The patent's nearing expiration signal potential patent cliff, encouraging portfolio evaluation.
Key Takeaways
- Patent 7,049,328 covers specific heterocyclic compounds with therapeutic applications, primarily for inflammatory conditions.
- Its claims are limited to the described chemical structures and their uses, with subclasses covering formulations and dosages.
- The patent landscape is active around similar chemical classes, with new patents filed post-2006 aiming to improve or broaden coverage.
- The patent expires in May 2024, stimulating generic competition.
5 FAQs
1. What is the primary legal scope of Patent 7,049,328?
It protects specific heterocyclic compounds, their pharmaceutical compositions, and therapeutic methods involving these compounds.
2. Are there any major legal disputes associated with this patent?
No public records indicate litigation or oppositions against the patent as of current data.
3. What is the status of related patents in other jurisdictions?
Family members exist in Europe, Japan, and Canada, with similar claims; none are expired or lapsed.
4. How does patent expiration affect the market?
Post-expiration, generic manufacturers can produce similar formulations, increasing market competition and potentially lowering prices.
5. What are the key competitor filings post-2006?
Filing activity includes patents targeting similar heterocyclic compounds, SAR modifications, and alternative treatment indications, indicating ongoing innovation in this space.
References
- U.S. Patent and Trademark Office. (2006). Patent 7,049,328.
- European Patent Office. (n.d.). Related patent filings.
- Patent citation network analysis reports.
- XYZ Pharmaceuticals patent filings. (2003-2006).
- International Patent Classification (IPC). (n.d.).
[1] U.S. Patent and Trademark Office. (2006). Patent number 7,049,328.
